Usage：Rimonabant is a selective antagonist of CB1 with IC50 of 13.6 nM and EC50 of 17.3 nM in hCB1 transfected HEK 293 membrane
AppearanceWhite crystalline powder
Package1kg/aluminium foil bag or as required
Usagecan be used as weightloss
Minimum order quantity10g
passmentProfessional team special for package and shipment and staring
on tracking code 24hours for customs pass guaranteed
ShippingBy express courier
Shipping leading timeWithin 24 hours after receiving the payment
Payment optionsWestern Union, MoneyGram, T/T,Bank transfer
shipping1)Express delivery with DHL,EMS,Fedex,HKEMS,TNT,UPS
(Express delivery within 24 hours after payment)
2)By sea (large quantity ,it will take 30-45days)
Rimonabant has also been shown to be a μ-opioid receptor antagonist (possibly the contributing factor in its reported dysphoric qualities).Its main effect is reduction in appetite.
In a 2006 (2 year) study reported in JAMA, "Compared with the placebo group, the 20 mg of rimonabant group produced greater mean (SEM) reductions in weight (-6.3 [0.2] kg vs -1.6 [0.2] kg; P<.001), waist circumference (-6.1 [0.2] cm vs -2.5 [0.3] cm; P<.001), and level of triglycerides (percentage change, -5.3 [1.2] vs 7.9 [2.0]; P<.001) and a greater increase in level of high-density lipoprotein cholesterol (percentage change, 12.6 [0.5] vs 5.4 [0.7]; P<.001)."
Rimonabant may also be found to be effective in assisting some smokers to quit smoking. Sanofi is currently conducting studies to determine the possible value of rimonabant in smoking-cessation therapy. The Studies with Rimonabant and Tobacco Use (STRATUS) program involves more than 6,000 subjects. STRATUS is designed to explore two smoking-related therapies: first, to use rimonabant directly to aid in smoking cessation; second, to help prevent weight gain in former smokers. Initial results apparently suggest rimonabant is effective for both uses. However, the FDA has explicitly stated to Sanofi that, without additional studies, rimonabant cannot be approved in the United States for smoking cessation therapy. According to a Cochrane Collaboration review in 2007, rimonabant "may increase the odds of quitting approximately 11/2-fold".
Product Tags：Rimonabant,168273-06-1,weight loss,Formestane,GBL,1,3-Dimethylpentylamine